Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops vs laser: cheap acne redness fix tested

NCT ID NCT07474883

Symptom relief Sponsor: Pham Ngoc Thach University of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if timolol eye drops, applied as a cream, can reduce the red marks left after acne. It compares the drops to intense pulsed light (IPL) therapy in 60 people aged 12 and older. The goal is to see if a simple, low-cost option can work as well as a laser treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
timolol 0.5% ophthalmic solution
What this could lead to
If it works, this could offer a cheap, easy-to-use cream for fading red marks left by acne, without needing expensive laser treatments.
What could go wrong
This is a very early, small study (60 people) testing a drug not originally made for skin. It may not work better than IPL, and side effects like irritation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria: * Age ≥ 12 years with a history of acne vulgaris. * Clinically diagnosed with post-inflammatory erythema (PIE) secondary to acne vulgaris. * Willing and able to provide informed consent (or assent with parental/guardian consent if under 18 years of age). Exclusion Criteria: * Refusal to participate or inability to comply with study procedures (examinations, treatment, follow-up visits), or loss to follow-up. * Presence of post-inflammatory hyperpigmentation (PIH) at the study site that may interfere with accurate assessment of erythema. * Presence of other dermatologic conditions affecting the treatment area (e.g., atopic dermatitis, rosacea, lupus erythematosus). * Known hypersensitivity or adverse reaction to timolol or other beta-adrenergic receptor blockers. * Pregnant or breastfeeding women. * History of cardiovascular or respiratory conditions contraindicating beta-blocker use (e.g., asthma, atrioventricular block, bradycardia \<50 beats per minute, hypotension). * Use of other topical medications or cosmetic products (except sunscreen) on the study area during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris Erythema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris Erythema Post inflammtory erythema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ho Chi Minh City Hospital of Dermato-Venereology

    RECRUITING

    Ho Chi Minh City, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.